Global Search | Novartis

Showing 2710 results

Press release / May 25, 2016

Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event

Outlines actions underway to accelerate launch of Entresto®, including further expansion of US primary care field force, and reinforce strong uptake of Cosentyx® Highlights…
Press release / Jun 06, 2016

Novartis pivotal data for Tafinlar® + Mekinist® demonstrated a 63 percent overall response rate in treating rare form of lung cancer

The median Duration of Response for BRAF V600E-mutant NSCLC patients treated with Tafinlar® + Mekinist® combination therapy was 9 months Efficacy analyses also presented for INC280 (…
Press release / Jun 04, 2016

Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna®

In ENESTfreedom, 51.6% of eligible first-line Tasigna patients maintained TFR for 48 weeks after stopping treatment; study did not meet its statistical primary endpoint, specifically the >…
Press release / Jun 08, 2016

Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016

Up to 80% of ankylosing spondylitis and 84% of psoriatic arthritis patients treated with Cosentyx® at two years had no radiographic progression in the spine or joints, respectively[1],[2] …
Press release / Jun 06, 2016

Novartis combination therapy Tafinlar® + Mekinist® demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma

Study is longest Ph III survival follow-up to date of BRAF V600E/K mutation-positive melanoma patients who received a targeted combination therapy Latest data show an estimated 44% of…
Press release / Jun 09, 2016

New data demonstrates Sandoz' etanercept and rituximab biosimilar candidates bioequivalent to originator products

Sandoz' biosimilar etanercept candidate shows pharmacokinetic (PK) bioequivalence with no clinically meaningful differences in safety, tolerability and immunogenicity to the originator.[1] …
Press release / Jun 08, 2016

Novartis announces AMG 334 significantly reduces patients' monthly migraine days in phase II study of chronic migraine prevention

Phase II 20120295 study of AMG 334 met primary endpoint, confirming efficacy and safety in patients with chronic migraine over 12 weeks of treatment Migraine is a leading cause of disability,…
Press release / Jun 10, 2016

Novartis highlights long-term safety data of Revolade® in adults with chronic immune thrombocytopenia, a rare blood disorder

EXTEND study provides long-term safety data for Revolade that are consistent with the findings from the pivotal Phase III RAISE study[1,2] Immune thrombocytopenia (ITP) is a rare and potentially…
Press release / Jun 10, 2016

Novartis presents data showing Jakavi® is superior to best available therapy in patients with less advanced polycythemia vera (PV)

Three times as many patients with inadequately controlled PV without enlarged spleen had hematocrit control without phlebotomy on Jakavi® (ruxolitinib) vs BAT[1] RESPONSE-2 complements data…
Press release / Jun 15, 2016

Novartis erweitert Partnerschaft mit Medicines for Malaria Venture zur Entwicklung von Malariamedikamenten der nächsten Generation

Novartis wird die Entwicklung des Malariapräparats KAF156 mit wissenschaftlicher und finanzieller Unterstützung von Medicines for Malaria Venture in Zusammenarbeit mit der Bill & Melinda Gates…